You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華海藥業(600521.SH):FDA對公司川南原料藥生產基地進口禁令已解除
格隆匯 11-17 15:44

格隆匯11月17日丨華海藥業(600521.SH)公佈,近日,公司收到美國FDA官方信函通知,FDA對公司川南原料藥生產基地進口禁令已解除。由此,公司川南生產基地生產的原料藥產品以及使用川南生產基地生產的原料藥製成的製劑產品,且在美國註冊批准的均可正常進入至美國市場。

上述FDA發出的進口禁令主要涉及的範圍為公司川南原料藥生產基地,涉及原料藥29個產品以及使用川南生產基地生產的原料藥製成的製劑產品。自受2018年下半年美國進口禁令的影響,到目前為止公司臨海川南生產基地生產的原料藥產品以及使用川南生產基地生產的原料藥製成的製劑產品均沒有出口到美國。

此次FDA解除進口禁令,將有利於公司美國市場銷售的逐步恢復,有利於提振公司的業績。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account